Middle East and Africa Asthma Drugs Market

The Middle East and Africa asthma drugs market is expected to reach US$ 2,041.34 million by 2028 from US$ 1,568.27 million in 2021; it is estimated to grow at a CAGR of 3.8% from 2021 to 2028.

The growth of the market is attributed to the rising prevalence of asthma and the increasing research activities and product innovations. However, the unmet medical needs hamper the market growth.

The treatment and management therapies for asthma have continued to develop with various drugs in the pipeline. Tezepelumab is a recently FDA-approved injection as an add-on maintenance treatment to improve severe asthma symptoms and the patient’s current asthma medicines. The drug targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine (cell-signaling proteins). Similarly, Masitinib, developed by AB Science, is an orally administered tyrosine kinase inhibitor that targets mast cells through inhibition of tyrosine kinases c-Kit, LYN, and FYN; it has recently been granted authorization by the French Medicine Agency to initiate a Phase III study to evaluate the drug in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS). Astegolimab is another promising monoclonal antibody showing promising efficacy in reducing asthma exacerbation rates. The emphasis on precision medicine for asthma control through the development of new asthma guidelines is also expected to create a positive change toward asthma drugs and individualized care.

In 2020, the FDA approved the triple therapy of fluticasone furoate, umeclidinium, and vilanterol (Trelegy Ellipta, GSK) for the treatment of asthma in patients aged 18 years and above. The approval was based on the CAPTAIN study (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler), which showed significant improvements in lung function after using the triple therapy compared to fluticasone furoate and vilanterol in a single daily dose and an easy-to-use inhaler.

Various other research and clinical studies point toward the growth of the asthma drugs market with drug combinations, novel drugs, and other modes of drug delivery under research. These developments have created several drugs that resulted in a positive change, and with the ongoing research landscape, further drug discovery and development are expected in the coming years.

Middle East and Africa Asthma Drugs Market Revenue and Forecast to 2028 (US$ Mn)

Get more information on this report Request Free Sample PDF

Middle East and Africa Asthma Drugs Strategic Insights

Strategic insights for the Middle East and Africa Asthma Drugs provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East and Africa Asthma Drugs Report Scope

Middle East and Africa Asthma Drugs Regional Insights

The geographic scope of the Middle East and Africa Asthma Drugs refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Middle East and Africa Asthma Drugs Market Segmentation

The Middle East and Africa asthma drugs market, by medication, is segmented into quick relief medications and long-term control medications. Based on route of administration, the market is segmented into inhaled, prefilled syringe/vials, and others.  Based on distribution channel, the Asia Pacific asthma drugs market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. By country, the market is segmented into the Saudi Arabia, South Africa, UAE and Rest of Middle East and Africa.

AstraZeneca; Teva Pharmaceutical Industries Ltd

;